O	0	1	A
O	2	7	pilot
O	8	19	multicentre
O	20	30	randomised
O	31	41	controlled
O	42	47	trial
O	48	50	of
B-intervention	51	60	lidocaine
I-intervention	61	69	infusion
O	70	72	in
O	73	78	women
O	79	89	undergoing
O	90	96	breast
O	97	103	cancer
O	104	111	surgery
O	111	112	.

O	113	120	Chronic
O	121	134	postoperative
O	135	139	pain
O	140	142	is
O	143	149	common
O	150	155	after
O	156	162	breast
O	163	169	cancer
O	170	177	surgery
O	177	178	.

O	179	183	Peri
O	183	184	-
O	184	193	operative
O	194	203	lidocaine
O	204	212	infusion
O	213	216	may
O	217	224	prevent
O	225	228	the
O	229	240	development
O	241	243	of
O	244	251	chronic
O	252	265	postoperative
O	266	270	pain
O	270	271	,
O	272	275	but
O	276	277	a
O	278	283	large
O	283	284	-
O	284	289	scale
O	290	295	trial
O	296	298	is
O	299	307	required
O	308	310	to
O	311	315	test
O	316	320	this
O	321	331	hypothesis
O	331	332	.

O	333	335	It
O	336	338	is
O	339	346	unclear
O	347	354	whether
O	355	356	a
O	357	366	pragmatic
O	366	367	,
O	368	379	multicentre
O	380	385	trial
O	386	392	design
O	393	397	that
O	398	400	is
O	401	411	consistent
O	412	416	with
O	417	423	expert
O	424	432	guidance
O	432	433	,
O	434	443	addresses
O	444	447	the
O	448	459	limitations
O	460	462	of
O	463	471	previous
O	472	479	studies
O	479	480	,
O	481	484	and
O	485	494	overcomes
O	495	503	existing
O	504	517	translational
O	518	526	barriers
O	527	529	is
O	530	534	safe
O	534	535	,
O	536	545	effective
O	546	549	and
O	550	558	feasible
O	558	559	.

O	560	562	We
O	563	572	conducted
O	573	574	a
O	575	581	double
O	581	582	-
O	582	587	blind
O	587	588	,
O	589	599	randomised
O	600	610	controlled
O	611	616	pilot
O	617	622	study
O	623	625	in
B-total-participants	626	629	150
B-eligibility	630	638	patients
I-eligibility	639	649	undergoing
I-eligibility	650	656	breast
I-eligibility	657	663	cancer
I-eligibility	664	671	surgery
O	672	678	across
O	679	684	three
O	685	694	hospitals
O	695	697	in
B-location	698	705	Western
I-location	706	715	Australia
O	715	716	.

O	717	725	Patients
O	726	734	received
O	735	744	lidocaine
O	744	745	,
O	746	748	or
O	749	759	equivalent
O	760	767	volumes
O	768	770	of
O	771	777	saline
O	777	778	,
O	779	781	as
O	782	784	an
O	785	796	intravenous
O	797	802	bolus
O	803	804	(
O	804	805	1
O	805	806	.
O	806	807	5
O	808	810	mg
O	810	811	.
O	812	814	kg
O	814	815	-
O	815	816	1
O	817	818	)
O	819	822	and
O	823	831	infusion
O	832	833	(
O	833	834	2
O	835	837	mg
O	837	838	.
O	839	841	kg
O	841	842	-
O	842	843	1
O	844	845	.
O	846	847	h
O	847	848	-
O	848	849	1
O	850	851	)
O	852	857	intra
O	857	858	-
O	858	869	operatively
O	869	870	,
O	871	874	and
O	875	876	a
O	877	889	subcutaneous
O	890	898	infusion
O	899	900	(
O	900	901	1
O	901	902	.
O	902	904	33
O	905	907	mg
O	907	908	.
O	909	911	kg
O	911	912	-
O	912	913	1
O	914	915	.
O	916	917	h
O	917	918	-
O	918	919	1
O	920	921	)
O	922	937	postoperatively
O	938	941	for
O	942	944	up
O	945	947	to
O	948	950	12
O	951	952	h
O	953	955	on
O	956	957	a
O	958	966	standard
O	967	975	surgical
O	976	980	ward
O	980	981	,
O	982	986	with
O	987	992	novel
O	993	999	safety
O	1000	1010	monitoring
O	1011	1016	tools
O	1017	1019	in
O	1020	1025	place
O	1025	1026	.

O	1027	1030	The
O	1031	1033	co
O	1033	1034	-
O	1034	1041	primary
O	1042	1050	outcomes
O	1051	1055	were
O	1055	1056	:
B-outcome-Measure	1057	1059	in
I-outcome-Measure	1059	1060	-
I-outcome-Measure	1060	1068	hospital
I-outcome-Measure	1069	1075	safety
I-outcome-Measure	1076	1082	events
O	1082	1083	;
B-outcome-Measure	1084	1089	serum
I-outcome-Measure	1090	1096	levels
I-outcome-Measure	1097	1099	of
I-outcome-Measure	1100	1109	lidocaine
I-outcome-Measure	1110	1116	during
I-outcome-Measure	1117	1128	intravenous
I-outcome-Measure	1129	1132	and
I-outcome-Measure	1133	1145	subcutaneous
I-outcome-Measure	1146	1154	infusion
O	1154	1155	;
O	1156	1159	and
B-outcome-Measure	1160	1170	annualised
I-outcome-Measure	1171	1180	enrolment
I-outcome-Measure	1181	1186	rates
O	1187	1190	per
O	1191	1195	site
O	1196	1200	with
O	1201	1205	long
O	1205	1206	-
O	1206	1210	term
O	1211	1215	data
O	1216	1223	capture
O	1223	1224	.

B-outcome	1225	1227	In
I-outcome	1227	1228	-
I-outcome	1228	1236	hospital
I-outcome	1237	1243	safety
I-outcome	1244	1250	events
O	1251	1255	were
O	1256	1260	rare
O	1260	1261	,
O	1262	1265	and
O	1266	1273	similar
O	1274	1276	in
O	1277	1280	the
B-control	1281	1288	placebo
O	1289	1292	and
O	1293	1302	lidocaine
O	1303	1307	arms
O	1308	1309	(
B-iv-bin-percent	1309	1310	3
I-iv-bin-percent	1310	1311	%
O	1312	1314	vs
O	1314	1315	.
B-cv-bin-percent	1316	1317	1
I-cv-bin-percent	1317	1318	%
O	1318	1319	)
O	1319	1320	.

O	1321	1327	Median
O	1328	1329	(
O	1329	1332	IQR
O	1333	1334	[
O	1334	1339	range
O	1339	1340	]
O	1340	1341	)
B-outcome	1342	1347	serum
I-outcome	1348	1357	lidocaine
I-outcome	1358	1364	levels
O	1365	1371	during
O	1372	1383	intravenous
O	1384	1385	(
O	1385	1386	2
O	1386	1387	.
O	1387	1389	16
O	1390	1391	(
O	1391	1392	1
O	1392	1393	.
O	1393	1395	74
O	1395	1396	-
O	1396	1397	2
O	1397	1398	.
O	1398	1400	83
O	1401	1402	[
O	1402	1403	1
O	1403	1404	.
O	1404	1406	12
O	1406	1407	-
O	1407	1408	6
O	1408	1409	.
O	1409	1411	06
O	1411	1412	]
O	1412	1413	)
O	1414	1415	µ
O	1415	1416	g
O	1416	1417	.
O	1418	1420	ml
O	1420	1421	-
O	1421	1422	1
O	1423	1424	,
O	1425	1426	n
O	1427	1428	=
O	1429	1431	41
O	1431	1432	)
O	1433	1436	and
B-outcome	1437	1449	subcutaneous
O	1450	1451	(
O	1451	1452	1
O	1452	1453	.
O	1453	1455	52
O	1456	1457	(
O	1457	1458	1
O	1458	1459	.
O	1459	1461	28
O	1461	1462	-
O	1462	1463	1
O	1463	1464	.
O	1464	1466	83
O	1467	1468	[
O	1468	1469	0
O	1469	1470	.
O	1470	1472	64
O	1472	1473	-
O	1473	1474	2
O	1474	1475	.
O	1475	1477	85
O	1477	1478	]
O	1478	1479	)
O	1480	1481	µ
O	1481	1482	g
O	1482	1483	.
O	1484	1486	ml
O	1486	1487	-
O	1487	1488	1
O	1489	1490	,
O	1491	1492	n
O	1493	1494	=
O	1495	1497	48
O	1497	1498	)
B-outcome	1499	1507	infusion
O	1508	1512	were
O	1513	1523	comparable
O	1524	1528	with
O	1529	1537	previous
O	1538	1544	trials
O	1545	1554	reporting
O	1555	1563	improved
O	1564	1568	pain
O	1569	1577	outcomes
O	1577	1578	.

O	1579	1589	Annualised
O	1590	1599	enrolment
O	1600	1612	approximated
O	1613	1615	50
O	1616	1624	patients
O	1625	1628	per
O	1629	1633	site
O	1634	1637	per
O	1638	1642	year
O	1642	1643	,
O	1644	1648	with
O	1649	1653	high
O	1654	1660	levels
O	1661	1663	of
O	1664	1672	protocol
O	1673	1682	adherence
O	1683	1686	and
O	1687	1688	≥
O	1689	1691	99
O	1691	1692	%
O	1693	1700	capture
O	1701	1703	of
O	1704	1712	outcomes
O	1713	1715	at
O	1716	1717	3
O	1718	1721	and
O	1722	1723	6
O	1724	1730	months
O	1730	1731	.

O	1732	1735	The
O	1736	1744	adjusted
O	1745	1749	odds
O	1750	1755	ratio
O	1756	1757	(
O	1757	1759	95
O	1759	1760	%
O	1760	1762	CI
O	1762	1763	)
O	1764	1767	for
B-outcome	1768	1781	postoperative
I-outcome	1782	1786	pain
I-outcome	1787	1789	at
I-outcome	1790	1791	6
I-outcome	1792	1798	months
O	1799	1801	in
O	1802	1805	the
O	1806	1815	lidocaine
O	1816	1819	arm
O	1820	1823	was
O	1824	1825	0
O	1825	1826	.
O	1826	1829	790
O	1830	1831	(
O	1831	1832	0
O	1832	1833	.
O	1833	1836	370
O	1836	1837	-
O	1837	1838	1
O	1838	1839	.
O	1839	1842	684
O	1842	1843	)
O	1843	1844	.

O	1845	1847	We
O	1848	1856	conclude
O	1857	1861	that
O	1862	1866	this
O	1867	1872	trial
O	1872	1873	,
O	1874	1876	as
O	1877	1885	designed
O	1885	1886	,
O	1887	1889	is
O	1890	1894	safe
O	1894	1895	,
O	1896	1905	effective
O	1906	1909	and
O	1910	1918	feasible
O	1919	1921	in
O	1922	1930	patients
O	1931	1941	undergoing
O	1942	1948	breast
O	1949	1955	cancer
O	1956	1963	surgery
O	1963	1964	,
O	1965	1968	and
O	1969	1970	a
O	1971	1977	larger
O	1977	1978	-
O	1978	1983	scale
O	1984	1989	trial
O	1990	1992	is
O	1993	2000	planned
O	2000	2001	.
